Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Dru...( Von Hoff details CTI's new ca...),Health

Von Hoff details CTI's new cancer drug development platform

SEATTLE, Nov. 14 /PRNewswire-FirstCall/ -- Analysts, fund managers, and investors heard first-hand the progress and prospects of three of Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC and MTAX: CTIC) oncology drug candidates, as well as information on a drug CTI expects to acquire this year, from an international panel of clinical investigators at a Company-sponsored analyst day entitled "New Strategies, New Opportunities" in New York on Friday, November 9.

Leading off the meeting was oncology drug development expert Daniel D. Von Hoff, M.D., Physician-in-Chief of the Translational Genomics Research Institute (TGen), Clinical Professor of Medicine at the University of Arizona, and Chief Scientific Officer at U.S. Oncology. Dr. Von Hoff introduced the emerging platform of using clinical and genomic evaluation of tumors to guide oncology clinical trials as a method to increase the likelihood of success while potentially decreasing development time and expense. "Leveraging its unique relationship with TGen, through their acquisition of Systems Medicine, CTI is one of the first companies to adopt this strategy of onco-genomic guided clinical trials," noted Von Hoff. "This represents an exciting convergence of genomics, small inhibitors of RNA (SiRNA), bioinformatics, and cancer drug development. You have to admire CTI for quickly integrating these powerful tools to design current and future clinical trials like those being conducted or contemplated for brostallicin," Von Hoff said. ZEVALIN(R) (Ibritumomab Tiuxetan)

Fredrick B. Hagemeister, M.D., Professor of Medicine at The University of Texas M. D. Anderson Cancer Center gave an overview o
'/>"/>